MedPath

A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer

Completed
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Other: tumor and peritumor radiomic feature
Registration Number
NCT06405815
Lead Sponsor
Jinling Hospital, China
Brief Summary

The investigators retrospectively collected the participants with T3 and T4, N0-2, M0 NSCLC patients resected between January 2013 to December 2021 for training and internal validation. The Clinical data, preoperative laboratory results and images were collected. High-risk margins were defined as R1 or R2 surgical margins or local recurrence during follow-up, and the investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSO was used to select the features and tumor radiomics model, peritumor model and combined model were built using 5-fold cross-validation. And it was further tested on the independent cohort. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), sensibility, specificity.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  • patients with T3 and T4 stage NSCLC;
  • available preoperative chest CTE within two weeks of surgery
Exclusion Criteria
  • inadequate imaging quality resulted from breathing artifact;
  • without regularly follow-up information on recurrence location and time

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
high-risk surgical margintumor and peritumor radiomic featureHigh-risk margins were defined as R1 or R2 surgical margins or local recurrence during follow-up.
Low-risk surgical margintumor and peritumor radiomic featureLow-risk margins were defined as R0 surgical margin meanwhile arising distant metastasis during follow-up.
Primary Outcome Measures
NameTimeMethod
disease free time and recurrence locationuntil the December 2023

the time from the surgery time to the recurrence time

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Jinling Hospital

🇨🇳

Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath